KL-6 in adult polymyositis and dermatomyositis patients and its correlation with interstitial lung disease

Egyptian Rheumatology and Rehabilitation

Table 3 Relation between KL-6 serum level and clinical data in patients group (n = 30)

	N	KL-6		Test of Sig	P
	N	Min.–Max	Mean ± SD	Test of Sig	P
Muscle power
Grade 0	1	1050.0–1300.0	1175.0 ± 176.8
Grade 1	2	920.0–1200.0	1042.0 ± 125.2	H = 35.882^*	< 0.001^*
Grade 2	2	740.0–1250.0	935.7 ± 169.6
Grade 3	11	115.0–1030.0	643.1 ± 316.0
Grade 3–4	5	100.0–758.0	375.4 ± 345.5
Grade 4	9	75.0–190.0	103.9 ± 37.25
Chest complain
Dyspnea
Free	15	75.0–100.0	86.70 ± 8.99	H = 38.107^*	< 0.001^*
Mild	6	115.0–190.0	148.5 ± 22.61
Moderate	5	700.0–1250.0	871.6 ± 147.5
Severe	4	710.0–1300.0	939.6 ± 180.8
Fatigue
No	10	75.0–100.0	86.70 ± 8.99	U = 0.0^*	< 0.001^*
Yes	20	115.0–1300.0	714.6 ± 360.3	U = 0.0^*	< 0.001^*
Dry cough
No	15	75.0–100.0	86.70 ± 8.99	U = 0.0^*	< 0.001^*
Yes	15	115.0–1300.0	714.6 ± 360.3	U = 0.0^*	< 0.001^*
Skin affection
No skin	10	75.0–100.0	86.70 ± 8.99	H = 43.622^*	< 0.001^*
Mild	10	115.0–190.0	148.50 ± 22.61
Moderate	5	700.0–990.0	815.0 ± 87.66
Severe	5	900.0–1300.0	1080.0 ± 138.08
Total skin score (CDASI) (n = 20) (score 0–132)				r = 0.881	< 0.001*

U Mann–Whitney test, H H for Kruskal–Wallis test, CDASI cutaneous disease area and severity index
r_s, *Spearman correlation coefficient (rho)
Bold values are significant at p < 0.05